Commercialisation Of Yondelis(R) For The Treatment Of Soft Tissue Sarcoma Approved In Russia

The Russian regulatory body has approved YONDELIS® (trabectedin) for the treatment of soft tissue sarcoma in adults. This represents another approval for YONDELIS® for treatment soft tissue sarcoma (STS) following upon its approval in Europe in September 2007, which opens up new opportunities in markets with enormous growth potential. Under the licensing agreement with Ortho Biotech Products, L.P., PharmaMar will receive royalties on sales of YONDELIS® in Russia.

More: continued here

Filed under: Cancer on November 25th, 2008